Updated July 2026 · 8 min read

Angiotensin II (Giapreza): The ICU Nurse's Guide

Part of the ICU Emergencies Hub — browse every related guide in one place.

Angiotensin II is the "third pathway" vasopressor — the drug you add when a patient is on high-dose catecholamines and vasopressin and the pressure still won't hold. It hits a receptor system the other pressors don't touch, which is exactly why it can rescue truly refractory vasodilatory shock. Here is the practical picture.

How angiotensin II works

Most ICU vasopressors work through two systems: catecholamines (norepinephrine, epinephrine, phenylephrine) acting on adrenergic receptors, and vasopressin acting on V1 receptors. Angiotensin II activates a third, independent system: the AT1 receptor of the renin-angiotensin-aldosterone axis. By recruiting a pathway the others don't use, it can raise blood pressure when the adrenergic and vasopressin systems are maxed out or downregulated — the definition of catecholamine-resistant shock. It also promotes aldosterone release and sodium/water retention.

Dosing and titration

Angiotensin II is titrated aggressively at first — often every few minutes — to reach the mean-arterial-pressure goal, then weaned as the patient stabilizes and other pressors come down. A striking feature seen in the shock trials is how quickly it can raise the MAP and allow the catecholamine doses to be reduced. It is delivered through a dedicated, well-monitored line with continuous arterial pressure, like any high-stakes pressor.

Safety concerns to monitor

Excessive vasoconstriction. Like any potent pressor, it can over-constrict — watch perfusion, extremities, and lactate, not just the number on the monitor.

Fluid retention. Aldosterone stimulation promotes sodium and water retention, a consideration in the volume-overloaded patient.

Where it fits in the shock ladder

The usual sequence in septic and other vasodilatory shock is norepinephrine first, then vasopressin added, then stress-dose steroids, with epinephrine and angiotensin II as further add-ons for refractory cases. Angiotensin II earns its place specifically because it works through a mechanism the earlier agents don't, making it a logical next step rather than "more of the same." It does not replace source control, volume optimization, or treating the underlying cause.

Why CRNA students should know it

On the CRNA path, angiotensin II is the cleanest bedside lesson in the renin-angiotensin system and in the concept of multi-pathway vasopressor support — the idea that when one receptor system is exhausted, recruiting another can restore perfusion. That reasoning, plus awareness of the thrombosis risk, is exactly the advanced hemodynamic thinking anesthesia and critical care value.

Bottom line

Angiotensin II is the third-pathway rescue pressor for refractory vasodilatory shock: it raises the MAP through the renin-angiotensin system when catecholamines and vasopressin have run out of room, sparing catecholamine dose. Respect the thrombosis risk with DVT prophylaxis, watch perfusion, and remember it is an add-on to — not a replacement for — source control and the rest of the shock bundle.

This article is general educational information for licensed clinicians and students, not medical advice or a substitute for your institution's protocols, pharmacy guidance, or a provider's orders. Always follow facility policy and verify every dose independently.